Document Detail


Reversal of severe angioproliferative pulmonary arterial hypertension and right ventricular hypertrophy by combined phosphodiesterase-5 and endothelin receptor inhibition.
MedLine Citation:
PMID:  25425003     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
BackgroundPatients with pulmonary arterial hypertension (PAH) are treated with vasodilators, including endothelin receptor antagonists (ERAs), phosphodiesterase-5 (PDE-5) inhibitors, soluble guanylyl cyclase activators, and prostacyclin. Despite recent advances in pharmacotherapy for individuals with PAH, morbidity and mortality rates in this patient population remain unacceptably high. Here, we tested the hypothesis that combination therapy with two PAH drugs that target distinct biochemical pathways will provide superior efficacy relative to monotherapy in the rat SU5416 plus hypoxia (SU-Hx) model of severe angioproliferative PAH, which closely mimics the human condition.MethodsMale Sprague Dawley rats were injected with a single dose of SU5416, which is a VEGF receptor antagonist, and exposed to hypobaric hypoxia for three weeks. Rats were subsequently housed at Denver altitude and treated daily with the PDE-5 inhibitor, tadalafil (TAD), the type A endothelin receptor (ETA) antagonist, ambrisentan (AMB), or a combination of TAD and AMB for four additional weeks.ResultsMonotherapy with TAD or AMB led to modest reductions in pulmonary arterial pressure (PAP) and right ventricular (RV) hypertrophy. In contrast, echocardiography and invasive hemodynamic measurements revealed that combined TAD/AMB nearly completely reversed pulmonary hemodynamic impairment, RV hypertrophy, and RV functional deficit in SU-Hx rats. Efficacy of TAD/AMB was associated with dramatic reductions in pulmonary vascular remodeling, including suppression of endothelial cell plexiform lesions, which are common in human PAH.ConclusionsCombined therapy with two vasodilators that are approved for the treatment of human PAH provides unprecedented efficacy in the rat SU-Hx preclinical model of severe, angioproliferative PAH.
Authors:
Maria A Cavasin; Kimberly M Demos-Davies; Katherine B Schuetze; Weston W Blakeslee; Matthew S Stratton; Rubin M Tuder; Timothy A McKinsey
Related Documents :
12576393 - Pulmonary eosinophilia following lung transplantation for sarcoidosis in two patients.
20846163 - The calpain inhibitor calpeptin prevents bleomycin-induced pulmonary fibrosis in mice.
7936673 - Early effects of cerebellopontine angle compression on rabbit distortion-product otoaco...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-11-26
Journal Detail:
Title:  Journal of translational medicine     Volume:  12     ISSN:  1479-5876     ISO Abbreviation:  J Transl Med     Publication Date:  2014 Nov 
Date Detail:
Created Date:  2014-11-26     Completed Date:  -     Revised Date:  2014-11-27    
Medline Journal Info:
Nlm Unique ID:  101190741     Medline TA:  J Transl Med     Country:  -    
Other Details:
Languages:  ENG     Pagination:  314     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  ANABOLIC RESPONSES TO ACUTE AND CHRONIC RESISTANCE EXERCISE ARE ENHANCED WHEN COMBINED WITH AQUATIC ...
Next Document:  Radiation response of mesenchymal stem cells derived from bone marrow and human pluripotent stem cel...